What is the current status of the Abbott Spinal Cord Stimulators lawsuit?

The Abbott Spinal Cord Stimulators litigation is currently emerging with 15 pending (per June 2026 petition) plaintiffs. Filing trend: New centralization petition filed June 2026; cases emerging in Illinois, California, New Jersey, Hawai'i and other jurisdictions.

Has there been a Abbott Spinal Cord Stimulators settlement?

No settlements in spinal cord stimulator litigation; Abbott Q4 2025 earnings included $165 million charge for 'legal reserves related to certain agreed-upon settlement'—product line unspecified

LexGeniusYour Edge in Mass Litigation

Pricing Daily Docket Track litigations free Sign in

Pending consolidation● EMERGING6 eventsMedical Device

Abbott Spinal Cord Stimulators

Q: What is the Abbott Spinal Cord Stimulators lawsuit about?

{"summary":"Abbott Laboratories faces individual product liability suits in federal courts — concentrated in the Northern District of Illinois — alleging defective spinal cord stimulators, unauthorized sales rep programming, and failure to warn. The Judicial Panel on Multidistrict Litigation declined consolidation, leaving cases to proceed separately. Representative filings include Melby v. Abbott

Q: What is the statute of limitations for Abbott Spinal Cord Stimulators claims?

{"generalNote":"Medical-device product-liability deadlines vary by state and usually run from injury, implant/explant, diagnosis, or discovery of a possible device connection. SCS cases may involve PMA preemption and FDA-related theories, so counsel should preserve device records and file-specific accrual facts early.","entries":[{"state":"California","duration":"Generally 2 years for personal inj

Medical Device · claims that Abbott spinal cord stimulator systems caused serious injuries including device migration, lead breakage, neurological deficits, worsened pain, and failed pain relief

Defendant

Abbott Laboratories

MDL / Track

MDL 3194

Various federal districts; N.D. Ill. has concentration

Judge

Various

Plaintiffs

15 pending (per June 2026 petition)

Bellwether / Trial

No verdicts yet

Settlement Status

No settlements in spinal cord stimulator litigation
Abbott Q4 2025 earnings included $165 million charge for 'legal reserves related to certain agreed-upon settlement'—product line unspecified

SharePost on X Share on Bluesky Share on LinkedIn Share on Facebook Email

Track litigations for free. Save this matter, capture notes, and monitor live signals.

← Torts Case overview Litigation status Geographic exposure Key defendants Timeline Statute of limitations Live activity News PubMed openFDA Court filings

Case overview

Abbott Laboratories faces individual product liability suits in federal courts — concentrated in the Northern District of Illinois — alleging defective spinal cord stimulators, unauthorized sales rep programming, and failure to warn. The Judicial Panel on Multidistrict Litigation declined consolidation, leaving cases to proceed separately. Representative filings include Melby v. Abbott Laboratories (N.D. Ill., filed March 13, 2026), Furia et al. v. Abbott Laboratories (N.D. Cal., filed March 2026), and Tuttle v. Abbott (Case No. 1:25-cv-15083, N.D. Ill., filed December 11, 2025).

Causation Theory

Plaintiffs allege Abbott's Proclaim, Infinity, and Eterna devices suffer from hardware and software defects causing painful electric shocks, unintended jolting, lead migration, battery failures, and loss of therapeutic benefit. Abbott issued a Class I recall for 155,028 Proclaim and Infinity implantable pulse generators due to Bluetooth communication failures that could prevent proper MRI mode entry or exit, exposing patients to risks of overheating, unintended stimulation, or tissue damage. A 2020 Public Citizen report found Abbott's original PMA P010032 was approved based on literature review rather than device-specific clinical trials, with 143 PMA supplements approved by end of 2019 covering redesigned leads, new batteries, and software updates.

Case Management Orders

Litigation status

Abbott spinal cord stimulator cases remain decentralized after the JPML denied centralization in June 2026 on technical grounds—four pending federal cases were all in the Northern District of Illinois, failing the 'different districts' statutory requirement. A new centralization petition was filed approximately June 22, 2026, identifying 15 pending cases and seeking assignment to the Central District of California alongside MDL-3181 (Boston Scientific), but no hearing date had been set as of August 2026.

MDL Track

MDL 3194

Abbott spinal cord stimulator products liability

State Court Activity

No state court MDL or coordinated proceeding reported

Geographic exposure

No national spinal cord stimulator device failure or patient injury events identified in search results. Single facility-level chemical storage emergency at Abbott Cardiovascular Systems Santa Clara; no patient population impact reported.

Santa Clara, California
Abbott Cardiovascular Systems facility at 3200 Lakeside Drive received emergency hazardous waste permit from California DTSC (SCH Number [PHONE]) for stabilization of 1,2 Dimethoxyethane — chemical fire/explosion risk required Clean Harbors intervention before off-site transport. March 27, 2025 regulatory filing.

Key defendants

Abbott Laboratories

Role: Manufacturer / primary product-liability defendant

The JPML memorandum targets Abbott spinal cord stimulator systems and alleges design, validation, warning, PMA-supplement, adverse-event, and post-market conduct common to the proposed MDL.

United States Food and Drug Administration

Role: APA defendant in many listed cases

Ten actions reportedly name FDA under the Administrative Procedure Act, alleging the agency failed to meaningfully review Abbott PMA submissions and supplements and unlawfully accepted serial supplement approvals.

Abbott SCS product line entities / successor device families

Role: Device-family evidence focus

The petition traces Abbott’s SCS line to the Genesis PMA P010032 and alleges later devices added material features through supplements without adequate independent clinical review.

Defendant	Role	Intelligence Note
Abbott Laboratories	Manufacturer / primary product-liability defendant	The JPML memorandum targets Abbott spinal cord stimulator systems and alleges design, validation, warning, PMA-supplement, adverse-event, and post-market conduct common to the proposed MDL.
United States Food and Drug Administration	APA defendant in many listed cases	Ten actions reportedly name FDA under the Administrative Procedure Act, alleging the agency failed to meaningfully review Abbott PMA submissions and supplements and unlawfully accepted serial supplement approvals.
Abbott SCS product line entities / successor device families	Device-family evidence focus	The petition traces Abbott’s SCS line to the Genesis PMA P010032 and alleges later devices added material features through supplements without adequate independent clinical review.

Timeline

2023-07
FDA Class I Recall: Proclaim and Infinity IPGs
Abbott initiates recall of 155,028 Proclaim and Infinity implantable pulse generators after devices became stuck in 'MRI mode,' risking overheating and tissue damage. FDA classified as Class I recall.
2026-02
Plaintiffs Seek Industry-Wide MDL Consolidation
Motion filed with U.S. Judicial Panel on Multidistrict Litigation to consolidate spinal cord stimulator cases against Abbott, Boston Scientific, Medtronic, and Nevro into single MDL in Northern District of Illinois. Abbott and Boston Scientific oppose.
2026-04
Multi-Plaintiff Suit Alleges 230 Undisclosed Modifications
Tuttle v. Abbott, No. 3:26-cv-01945 (N.D. Cal.): Complaint alleges Proclaim Elite SCS underwent over 230 undisclosed post-approval modifications to firmware, battery, and stimulation architecture. Seeks APA enforcement against FDA.
2026-06-05
JPML Denies Abbott MDL, Cites Single-District Technicality
U.S. Judicial Panel on Multidistrict Litigation denies centralization for Abbott cases in MDL No. 3181, finding all four pending federal cases resided in same district (N.D. Ill.), failing 28 U.S.C. § 1407's 'different districts' requirement. Panel noted denial 'does not foreclose' future centralization if cases filed in other districts.
2026-06-05
Boston Scientific MDL 3181 Established
JPML establishes MDL No. 3181 for Boston Scientific spinal cord stimulator cases, transferring 23 actions to Central District of California before Judge Josephine L. Staton.
2026-06-29
Abbott Litigation Remains Decentralized
Federal Abbott cases proceed individually in Northern District of Illinois and other jurisdictions including California, New Jersey, and Hawaii. No nationwide settlement program announced. New filings continue as statute of limitations deadlines approach.

Statute of limitations

Medical-device product-liability deadlines vary by state and usually run from injury, implant/explant, diagnosis, or discovery of a possible device connection. SCS cases may involve PMA preemption and FDA-related theories, so counsel should preserve device records and file-specific accrual facts early.

⚠ 4 states with critical SOL — act immediately

⚠California

Generally 2 years for personal injury

Rule: Product-injury claims typically accrue on injury or discovery of facts suggesting wrongful cause.

Discovery: Discovery rule may defer accrual until plaintiff suspects or should suspect device-related injury.

⚠Texas

Generally 2 years for personal injury

Rule: Accrual often begins when injury occurs, subject to limited discovery principles for latent injury.

⚠Pennsylvania

Generally 2 years for personal injury

Rule: Discovery rule may apply where device causation was not reasonably knowable.

⚠Illinois

Generally 2 years for personal injury

Rule: Discovery rule focuses on when plaintiff knew or should have known injury may be wrongfully caused.

State	SOL	Rule	Discovery Rule	Notes
⚠California	Generally 2 years for personal injury	Product-injury claims typically accrue on injury or discovery of facts suggesting wrongful cause.	Discovery rule may defer accrual until plaintiff suspects or should suspect device-related injury.	—
⚠Texas	Generally 2 years for personal injury	Accrual often begins when injury occurs, subject to limited discovery principles for latent injury.	—	—
⚠Pennsylvania	Generally 2 years for personal injury	Discovery rule may apply where device causation was not reasonably knowable.	—	—
⚠Illinois	Generally 2 years for personal injury	Discovery rule focuses on when plaintiff knew or should have known injury may be wrongfully caused.	—	—

Live intelligence

AI litigation brief

Abbott Spinal Cord Stimulators remains pending consolidation with 6 current signals in the accepted feed.

Overview

Key developments

PR Newswire news on Jul 22: Wisner Baum's Lawsuits Challenge FDA Oversight of Spinal Cord Implants - PR Newswire
MAUDE FDA alert on May 7: MAUDE Filing 25112514: ABBOTT NEUROSTIMULATOR

Trajectory

Press and regulatory signals are moving in tandem for Abbott SCS. The next escalation check is whether these agency actions prompt new PACER filings or MDL scheduling orders.

Editorial intelligence

MDL 3194 should stay on the lead docket watch because it is the primary consolidation vehicle for Abbott SCS.

Generated Aug 12, 2026, 2:00 AM UTC

6 events detected

Google News (3)

No recent PubMed signals. Monitoring is active — this section updates automatically.

No recent court filing signals. Monitoring is active — this section updates automatically.

Workbench

LexGenius Ranking

82Score

Court, news, and regulatory activity are elevated

Evidence16 / 20

Momentum14 / 20

Exposure16 / 20

Regulatory16 / 20

Legal20 / 20

Monitoring

Live

monitoring

Last: Aug 12, 2026, 2:00 AM UTC

Next: —

Source Monitoring

PACER

3m 00s

PACER

Pending

Google News

3m 00s

MAUDE

13m 00s

PubMed

28m 00s

Event feed

events detected

Google NewsMAUDE

AI Brief

Abbott Spinal Cord Stimulators remains pending consolidation with 6 current signals in the accepted feed.

Overview

Key developments

PR Newswire news on Jul 22: Wisner Baum's Lawsuits Challenge FDA Oversight of Spinal Cord Implants - PR Newswire. ‖ MAUDE FDA alert on May 7: MAUDE Filing 25112514: ABBOTT NEUROSTIMULATOR.

Generated Aug 12, 2026, 2:00 AM UTC

Tracked MDLs

MDL 3194

Pending consolidation

Abbott spinal cord stimulator products liability

Motion to Consolidate

← Previous

Zantac

Tracks ranitidine litigation, product-safety developments, and medical reporting connected to Zantac claims.

Nevro Spinal Cord Stimulators

Tracks pending JPML consolidation proceedings alleging Nevro HFX, Senza, and Omnia spinal cord stimulator systems caused neurological injury, device malfunction, and failed pain relief.

Pending consolidation● EMERGING6 eventsMedical Device

Abbott Spinal Cord Stimulators

Medical Device · claims that Abbott spinal cord stimulator systems caused serious injuries including device migration, lead breakage, neurological deficits, worsened pain, and failed pain relief

Defendant

Abbott Laboratories

MDL / Track

MDL 3194

Various federal districts; N.D. Ill. has concentration

Judge

Various

Plaintiffs

15 pending (per June 2026 petition)

Bellwether / Trial

No verdicts yet

Settlement Status

No settlements in spinal cord stimulator litigation
Abbott Q4 2025 earnings included $165 million charge for 'legal reserves related to certain agreed-upon settlement'—product line unspecified

SharePost on X Share on Bluesky Share on LinkedIn Share on Facebook Email

Track litigations for free. Save this matter, capture notes, and monitor live signals.

← Torts Case overview Litigation status Geographic exposure Key defendants Timeline Statute of limitations Live activity News PubMed openFDA Court filings

Case overview

Causation Theory

Case Management Orders

Litigation status

MDL Track

MDL 3194

Abbott spinal cord stimulator products liability

State Court Activity

No state court MDL or coordinated proceeding reported

Geographic exposure

Santa Clara, California
Abbott Cardiovascular Systems facility at 3200 Lakeside Drive received emergency hazardous waste permit from California DTSC (SCH Number [PHONE]) for stabilization of 1,2 Dimethoxyethane — chemical fire/explosion risk required Clean Harbors intervention before off-site transport. March 27, 2025 regulatory filing.

Key defendants

Abbott Laboratories

Role: Manufacturer / primary product-liability defendant

The JPML memorandum targets Abbott spinal cord stimulator systems and alleges design, validation, warning, PMA-supplement, adverse-event, and post-market conduct common to the proposed MDL.

United States Food and Drug Administration

Role: APA defendant in many listed cases

Abbott SCS product line entities / successor device families

Role: Device-family evidence focus

The petition traces Abbott’s SCS line to the Genesis PMA P010032 and alleges later devices added material features through supplements without adequate independent clinical review.

Defendant	Role	Intelligence Note
Abbott Laboratories	Manufacturer / primary product-liability defendant	The JPML memorandum targets Abbott spinal cord stimulator systems and alleges design, validation, warning, PMA-supplement, adverse-event, and post-market conduct common to the proposed MDL.
United States Food and Drug Administration	APA defendant in many listed cases	Ten actions reportedly name FDA under the Administrative Procedure Act, alleging the agency failed to meaningfully review Abbott PMA submissions and supplements and unlawfully accepted serial supplement approvals.
Abbott SCS product line entities / successor device families	Device-family evidence focus	The petition traces Abbott’s SCS line to the Genesis PMA P010032 and alleges later devices added material features through supplements without adequate independent clinical review.

Timeline

2023-07
FDA Class I Recall: Proclaim and Infinity IPGs
Abbott initiates recall of 155,028 Proclaim and Infinity implantable pulse generators after devices became stuck in 'MRI mode,' risking overheating and tissue damage. FDA classified as Class I recall.
2026-02
Plaintiffs Seek Industry-Wide MDL Consolidation
Motion filed with U.S. Judicial Panel on Multidistrict Litigation to consolidate spinal cord stimulator cases against Abbott, Boston Scientific, Medtronic, and Nevro into single MDL in Northern District of Illinois. Abbott and Boston Scientific oppose.
2026-04
Multi-Plaintiff Suit Alleges 230 Undisclosed Modifications
Tuttle v. Abbott, No. 3:26-cv-01945 (N.D. Cal.): Complaint alleges Proclaim Elite SCS underwent over 230 undisclosed post-approval modifications to firmware, battery, and stimulation architecture. Seeks APA enforcement against FDA.
2026-06-05
JPML Denies Abbott MDL, Cites Single-District Technicality
U.S. Judicial Panel on Multidistrict Litigation denies centralization for Abbott cases in MDL No. 3181, finding all four pending federal cases resided in same district (N.D. Ill.), failing 28 U.S.C. § 1407's 'different districts' requirement. Panel noted denial 'does not foreclose' future centralization if cases filed in other districts.
2026-06-05
Boston Scientific MDL 3181 Established
JPML establishes MDL No. 3181 for Boston Scientific spinal cord stimulator cases, transferring 23 actions to Central District of California before Judge Josephine L. Staton.
2026-06-29
Abbott Litigation Remains Decentralized
Federal Abbott cases proceed individually in Northern District of Illinois and other jurisdictions including California, New Jersey, and Hawaii. No nationwide settlement program announced. New filings continue as statute of limitations deadlines approach.

Statute of limitations

⚠ 4 states with critical SOL — act immediately

⚠California

Generally 2 years for personal injury

Rule: Product-injury claims typically accrue on injury or discovery of facts suggesting wrongful cause.

Discovery: Discovery rule may defer accrual until plaintiff suspects or should suspect device-related injury.

⚠Texas

Generally 2 years for personal injury

Rule: Accrual often begins when injury occurs, subject to limited discovery principles for latent injury.

⚠Pennsylvania

Generally 2 years for personal injury

Rule: Discovery rule may apply where device causation was not reasonably knowable.

⚠Illinois

Generally 2 years for personal injury

Rule: Discovery rule focuses on when plaintiff knew or should have known injury may be wrongfully caused.

State	SOL	Rule	Discovery Rule	Notes
⚠California	Generally 2 years for personal injury	Product-injury claims typically accrue on injury or discovery of facts suggesting wrongful cause.	Discovery rule may defer accrual until plaintiff suspects or should suspect device-related injury.	—
⚠Texas	Generally 2 years for personal injury	Accrual often begins when injury occurs, subject to limited discovery principles for latent injury.	—	—
⚠Pennsylvania	Generally 2 years for personal injury	Discovery rule may apply where device causation was not reasonably knowable.	—	—
⚠Illinois	Generally 2 years for personal injury	Discovery rule focuses on when plaintiff knew or should have known injury may be wrongfully caused.	—	—

Live intelligence

AI litigation brief

Abbott Spinal Cord Stimulators remains pending consolidation with 6 current signals in the accepted feed.

Overview

Key developments

PR Newswire news on Jul 22: Wisner Baum's Lawsuits Challenge FDA Oversight of Spinal Cord Implants - PR Newswire
MAUDE FDA alert on May 7: MAUDE Filing 25112514: ABBOTT NEUROSTIMULATOR

Trajectory

Press and regulatory signals are moving in tandem for Abbott SCS. The next escalation check is whether these agency actions prompt new PACER filings or MDL scheduling orders.

Editorial intelligence

MDL 3194 should stay on the lead docket watch because it is the primary consolidation vehicle for Abbott SCS.

Generated Aug 12, 2026, 2:00 AM UTC

6 events detected

Google News (3)

No recent PubMed signals. Monitoring is active — this section updates automatically.

No recent court filing signals. Monitoring is active — this section updates automatically.

Workbench

LexGenius Ranking

82Score

Court, news, and regulatory activity are elevated

Evidence16 / 20

Momentum14 / 20

Exposure16 / 20

Regulatory16 / 20

Legal20 / 20

Monitoring

Live

monitoring

Last: Aug 12, 2026, 2:00 AM UTC

Next: —

Source Monitoring

PACER

3m 00s

PACER

Pending

Google News

3m 00s

MAUDE

13m 00s

PubMed

28m 00s

Event feed

events detected

Google NewsMAUDE

AI Brief

Abbott Spinal Cord Stimulators remains pending consolidation with 6 current signals in the accepted feed.

Overview

Key developments

PR Newswire news on Jul 22: Wisner Baum's Lawsuits Challenge FDA Oversight of Spinal Cord Implants - PR Newswire. ‖ MAUDE FDA alert on May 7: MAUDE Filing 25112514: ABBOTT NEUROSTIMULATOR.

Generated Aug 12, 2026, 2:00 AM UTC

Tracked MDLs

MDL 3194

Pending consolidation

Abbott spinal cord stimulator products liability

Motion to Consolidate

← Previous

Zantac

Tracks ranitidine litigation, product-safety developments, and medical reporting connected to Zantac claims.

Nevro Spinal Cord Stimulators

Tracks pending JPML consolidation proceedings alleging Nevro HFX, Senza, and Omnia spinal cord stimulator systems caused neurological injury, device malfunction, and failed pain relief.